Shares of Denmark’s pharmaceutical company Novo Nordisk (NYSE: NVO) fell by 4% following the termination of its partnership with telehealth firm Hims & Hers, which Novo Nordisk accused of illegal practices and deceptive marketing. Hims & Hers CEO Andrew Dudum is preparing a response to the allegations made against the company.
Explain It To Me Like I’m 5: Shares of Novo Nordisk, a big medicine company from Denmark, dropped 4% because they ended a partnership with another company, Hims & Hers, after saying they were not following the rules.
Want More Context? 🔎
